Comment from Lisa Pellegrino
AnonymousSupportIndividual
Summary: The commenter supports the prioritization of off-label use of existing medications to treat long Covid. They argue that the lack of FDA-approved treatments is hampering healthcare providers and that clinical evidence should be used to address the millions of people suffering from the condition.
Estimates indicate that up to 16.3% of individuals who have been infected with Covid, develop long Covid. This translates to millions of Americans and is growing each day as more people contract the disease. Healthcare providers who treat long Covid patients are hampered by a lack of FDA approved treatments. Off label use of existing medications to treat long Covid should be prioritized as clinical evidence to support their use exists and all reasonable efforts must be explored to treat the millions that are suffering with the effects of their Covid infections.